Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | PNMT | P11086 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8934433 | 0.70 | NPC1 (0.38) | HTR2ADRD2SLC6A2HTR2CSLC6A4 | |
| SCHEMBL524602 | 0.64 | PNMT (0.63) | DRD2PNMTNPC1RAB9APGR | |
| SCHEMBL30103334 | 0.64 | PNMT (0.63) | DRD2PNMTNPC1RAB9APGR | |
| SCHEMBL8227124 | 0.64 | HTR2A (0.56) | HTR2ADRD2SLC6A2HTR2CSLC6A4 | |
| SCHEMBL2877998 | 0.62 | PNMT (0.61) | DRD2PNMTNPC1RAB9APGR | |
| SCHEMBL4882972 | 0.62 | HTR2A (0.54) | HTR2ADRD2SLC6A2HTR2CSLC6A4 | |
| SCHEMBL1721596 | 0.62 | HTR2A (0.54) | HTR2ADRD2SLC6A2HTR2CSLC6A4 | |
| SCHEMBL31059131 | 0.62 | HTR2A (0.54) | HTR2ADRD2SLC6A2HTR2CSLC6A4 | |
| SCHEMBL28698022 | 0.62 | PNMT (0.41) | HTR2ADRD2HTR2CPNMTNPC1 | |
| SCHEMBL3643453 | 0.62 | HTR2A (0.62) | HTR2ADRD2SLC6A2HTR2CSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246918-A1 | COMPOUNDS AND COMPOSITIONS AS EIF4E INHIBITORS AND THE USES THEREOF | RIBOMETRIX, INC. | 2024-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246918-A1 | COMPOUNDS AND COMPOSITIONS AS EIF4E INHIBITORS AND THE USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | HTR2A 4518/4885DRD2 4842/4885SLC6A2 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.